Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
2.070
0.00 (0.00%)
May 19, 2025, 4:00 PM - Market open
Kyverna Therapeutics Stock Forecast
KYTX's stock price has decreased by -86.58% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 5 professional analysts, the 12-month price target for Kyverna Therapeutics stock ranges from a low of $4.00 to a high of $33. The average analyst price target of $18.8 forecasts a 808.21% increase in the stock price over the next year.
Price Target: $18.80 (+808.21%)
Analyst Consensus: Buy
* Price targets were last updated on Apr 3, 2025.
Analyst Ratings
The average analyst rating for Kyverna Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $6 → $4 | Hold | Maintains | $6 → $4 | +93.24% | Apr 3, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $40 → $20 | Buy | Maintains | $40 → $20 | +866.18% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +189.86% | Nov 20, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $44 → $24 | Buy | Maintains | $44 → $24 | +1,059.42% | Nov 15, 2024 |
| UBS | UBS | Strong Buy Initiates $13 | Strong Buy | Initiates | $13 | +528.02% | Oct 10, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-3.97
from -3.33
EPS Next Year
-3.55
from -3.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 4.5M | ||
| Avg | n/a | n/a | 1.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.63 | -1.63 | -3.39 | ||
| Avg | -3.97 | -3.55 | -4.27 | ||
| Low | -4.11 | -4.21 | -4.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.